GenKyoTex (Switzerland) a clinical-stage pharmaceutical company focused on the treatment of complications of diabetes including diabetic nephropathy, closed a $20.8M Series C financing. Participants include Edmond de Rothschild Investment Partners, Vesalius Biocapital, MP Healthcare Venture Management and Specialized European Fund for Therapeutic Innovation.